echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 330 million dollars!

    330 million dollars!

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Eli Lilly announced today that the US government has purchased additional neutralizing antibody therapy authorized by it for emergency use to treat COVID-19


    The recent increase in COVID-19 cases has led to a substantial increase in the utilization of monoclonal antibody drugs, especially in areas with low vaccination rates across the country


    Pseudovirus and real virus studies have shown that the double antibody therapy of esvirizumab and banivirimab retains the neutralizing activity of alpha and delta mutations


    It is reported that at the beginning of the outbreak in 2020, the local innovative pharmaceutical company Junshi Biotechnology and the Institute of Microbiology of the Chinese Academy of Sciences jointly developed a neutralizing antibody against the new coronavirus, esvirizumab.


    At present, diabody therapy has been authorized for emergency use in 12 countries and regions including the United States and Italy


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.